In brief, our findings indicate that CBX4 is essential for tumorigenesis by initiating YAP1 function in the nucleus to maintain CSC capabilities and is a good therapeutic target for preventing and treating tumours as well as evaluating the prognosis in patients with SR HCC. The gene discussed is YAP1; the disease is hepatocellular carcinoma.